Clinical Trials

Nasopharyngeal Carcinoma

NCT06788002 2026-04-02

Light

26 enrolled

Nasopharyngeal Carcinoma

NCT05941741 2026-03-18

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Nasopharyngeal Carcinoma

NCT07362979 2026-03-17

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

243 enrolled

Nasopharyngeal Carcinoma

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

266 enrolled

Nasopharyngeal Carcinoma

NCT07412314 2026-03-09

Proton Therapy for Recurrent Nasopharyngeal Carcinoma

52 enrolled

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Nasopharyngeal Carcinoma

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT07327216 2026-03-04

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

180 enrolled

Nasopharyngeal Carcinoma

NCT06059261 2026-02-18

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

30 enrolled

Nasopharyngeal Carcinoma

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

28 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

24 enrolled

Nasopharyngeal Carcinoma

NCT07101744 2026-01-23

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

41 enrolled

Nasopharyngeal Carcinoma

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

300 enrolled

Nasopharyngeal Carcinoma

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

456 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

346 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT01365169 2026-01-07

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

GastrointestinalHead & Neck

590 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Somatostatinoma, Colorectal Neoplasms

NCT07303023 2025-12-24

INCIPT-NPC

462 enrolled

Nasopharyngeal Carcinoma

NCT07277764 2025-12-11

REDEFINE

23 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT07188584 2025-12-09

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

166 enrolled

Nasopharyngeal Carcinoma

NCT06982300 2025-10-03

NACASOR

Phase 1/2 Recruiting

10 enrolled

Nasopharyngeal Carcinoma

NCT06509009 2025-09-19

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

30 enrolled

Nasopharyngeal Carcinoma

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

208 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06241612 2025-09-17

Individualized Elective Neck Irradiation in NPC Patients

470 enrolled

Nasopharyngeal Carcinoma

NCT05884983 2025-08-15

Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma

Recruiting

12,000 enrolled

Nasopharyngeal Carcinoma

NCT06177301 2025-08-14

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

266 enrolled

Nasopharyngeal Carcinoma

NCT07085988 2025-07-25

Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

109 enrolled

CNSDermatologicGastrointestinalHead & NeckOther solid neoplasmSarcomaThoracic

Nasopharyngeal Carcinoma

NCT07072143 2025-07-18

PARTNER

Recruiting

6,250 enrolled

Pleuropulmonary blastoma, Nasopharyngeal Carcinoma, Adrenal Cortex Neoplasms, Melanoma, Mesothelioma, Pancreatic Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors

NCT07067268 2025-07-16

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

76 enrolled

Nasopharyngeal Carcinoma

NCT05147844 2025-07-14

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

40 enrolled

Nasopharyngeal Carcinoma

NCT06228079 2025-07-04

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

176 enrolled

Nasopharyngeal Carcinoma

NCT07019870 2025-06-13

Screening for Early Diagnosis of Nose Cancer

20,000 enrolled

Nasopharyngeal Carcinoma

NCT06235203 2025-06-03

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

154 enrolled

Nasopharyngeal Carcinoma

NCT07000643 2025-06-03

Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma

386 enrolled

Nasopharyngeal Carcinoma

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

70 enrolled

Nasopharyngeal Carcinoma

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

148 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06682442 2025-04-20

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

66 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT06662058 2025-04-10

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

118 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06752239 2025-04-10

PROTECT-NPC

474 enrolled

Nasopharyngeal Carcinoma, Radiation Injuries, Thyroid Diseases

NCT05508347 2025-04-09

Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma

170 enrolled

Nasopharyngeal Carcinoma

NCT06886347 2025-03-20

Metastatic Nasopharyngeal Carcinoma

Phase 1 Recruiting

47 enrolled

Nasopharyngeal Carcinoma

NCT06712888 2025-03-18

Navigation

466 enrolled

Nasopharyngeal Carcinoma

NCT06870435 2025-03-11

Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas

68,649 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT06851247 2025-02-28

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

47 enrolled

Nasopharyngeal Carcinoma

NCT06852638 2025-02-28

CD70-targeted immunoPET Imaging of Malignant Cancers